Several Justices seemed skeptical about plaintiffs’ standing in a Supreme Court case challenging the FDA’s approval of mifepristone. Dean Rebouche says a dismissal on such grounds will likely not deter future litigation with different plaintiffs.
Published on April 11, 2024
Are the busiest abortion clinics about to get busier?
